Chemistry:Ramatroban
 | |
| Clinical data | |
|---|---|
| Trade names | Baynas |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H21FN2O4S |
| Molar mass | 416.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ramatroban (INN) (also known as BAY u3405)[1] is a thromboxane receptor antagonist.[2]
It is also a DP2 receptor antagonist.[3]
It is indicated for the treatment of coronary artery disease.[4] It has also been used for the treatment of asthma.[5]
It has been suggested that ramatroban, by modulating DP2 receptor, can reverse viremia-associated proinflammatory and prothrombotic processes which are similar to those induced by SARS-Cov-2.[citation needed] Hence, ramatroban, that has been used for the treatment of allergic rhinitis in Japan for the past two decades with a well established safety profile, merits investigation as a novel immunotherapy for the treatment of COVID-19 disease, although no clinical trial has yet been conducted.[6]
Ramatroban was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer Yakuhin then marketed by Kyorin Pharmaceutical and Nippon Shinyaku Co., Ltd. under the trade name Baynas.
References
- ↑ "Ramatroban (compound)". National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Ramatroban.
- ↑ "An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro". The Journal of Pharmacology and Experimental Therapeutics 305 (1): 347–352. April 2003. doi:10.1124/jpet.102.046748. PMID 12649388.
- ↑ "A novel antagonist of prostaglandin D2 blocks the locomotion of eosinophils and basophils". European Journal of Clinical Investigation 38 (9): 663–671. September 2008. doi:10.1111/j.1365-2362.2008.01989.x. PMID 18837743.
- ↑ "Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease". Stroke 21 (12 Suppl): IV149–IV151. December 1990. PMID 2260140. http://pt.wkhealth.com/pt/re/stroke/pdfhandler.00007670-199012001-00037.pdf.
- ↑ "[Thromboxane A2 receptor antagonist in asthma therapy]" (in ja). Nihon Rinsho. Japanese Journal of Clinical Medicine 54 (11): 3045–3048. November 1996. PMID 8950952.
- ↑ "Pharmaco-Immunomodulatory Therapy in COVID-19". Drugs 80 (13): 1267–1292. September 2020. doi:10.1007/s40265-020-01367-z. PMID 32696108.
External links
- (in Japanese) Baynas Tablets Prescribing Information
 |  |
